As expected, when compared to ER+ or HER2+ breast cancers within our cohort, the triple negative breast cancers displayed a higher pathologic grade, higher clinical stage, higher frequency of CIN, higher frequency of aberrant TP53 IHC, higher Ki67 index, higher average ploidy, and higher average centrosome number (Supplemental Tables 1 and 2). The gene discussed is ERBB2; the disease is breast cancer.